Search Browse Earnings

Biohaven Ltd. — SlamSEC

Biohaven Ltd.

NYSE:BHVN

Pharmaceutical Preparations·NEW HAVEN, CT

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$429.1M

FY 2025

Net Income

-$408.2M

FY 2025

EPS (Diluted)

-$5.73

FY 2025

Stock Price

$10.46

+1.9%

2026-03-11

52W Range

$7.48 – $31.18

P/E Ratio

-1.8x

Market Cap

$1.6B

Cash

$248.4M

FY 2025

Total Debt

—

Net Cash

$248.4M

FY 2025

Enterprise Value

$1.3B

Debt / EBITDA

0.6x

FY 2025

EV / EBITDA

-3.1x

Employees

—

CEO

Coric Vlad

CFO

Buten Matthew